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Background: Effective inhibition of plasma kallikrein may have significant benefits
for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1-INH-
HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small mole-
cule inhibitor of plasma kallikrein. This study (OPuS-2) evaluated the efficacy and
safety of prophylactic avoralstat 300 or 500 mg compared with placebo.
Methods: OPuS-2 was a Phase 3, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study. Subjects were administered avoralstat 300 mg, avo-
ralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy
endpoint was the angioedema attack rate based on adjudicator-confirmed attacks.
Results: A total of 110 subjects were randomized and dosed. The least squares (LS)
mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving
avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject
in each of the avoralstat groups and no subjects in the placebo group were attack-
free during the 84-day treatment period. The LS mean duration of all confirmed
attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat
300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life
Questionnaire (AE-QoL), improved QoL was observed for the avoralstat 500 mg
group compared with placebo. Avoralstat was generally safe and well tolerated.
Conclusions: Although this study did not demonstrate efficacy of avoralstat in pre-
venting angioedema attacks in C1-INH-HAE, it provided evidence of shortened
angioedema episodes and improved QoL in the avoralstat 500 mg treatment group
compared with placebo.
K E YWORD S
C1 inhibitor, hereditary angioedema, oral kallikrein inhibitor, prophylaxis
1 | BACKGROUND
Hereditary angioedema (HAE) with C1 inhibitor deficiency (C1-INH-
HAE) is an autosomal dominant disorder characterized by recurrent
episodes of swelling of the skin, pharynx, larynx, gastrointestinal tract,
genitals, and extremities,1 and is due primarily to mutations in the SERP-
ING1 gene that results in insufficient production of the natural plasma
kallikrein inhibitor, C1 inhibitor (C1-INH). C1-INH is a serine protease
inhibitor (serpin) that prevents uncontrolled contact activation and
bradykinin (BK) production by covalently binding to and inactivating
kallikrein, a serine protease integral to the contact activation pathway.2
Extensive evidence from animal models and clinical studies supports the
role of BK as the principal mediator of the signs and symptoms of
C1-INH-HAE.3-5 Activation of the BK B2 receptor by BK results in vasodi-
latation, increased vascular permeability, and smooth muscle contraction,
all of which contribute to the angioedema attacks in C1-INH-HAE
patients.3 Oropharyngeal and laryngeal swelling can be life-threatening.
Angioedema attacks in other sites, including the limbs, genitalia, face, and
intestines, can be painful, disabling, and disfiguring, and have a significant
impact on functionality and quality of life of the patients.6-9
The effective management of C1-INH-HAE involves the preven-
tion and treatment of angioedema attacks.10 Kallikrein is a proven tar-
get in the treatment of C1-INH-HAE. In the EU and the United States,
licensed therapy for long-term or routine prevention of angioedema
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attacks is limited to purified plasma-derived C1-INH administered
intravenously (Cinryze) or subcutaneously (Haegarda – USA only)
every 3-4 days; oral doses of attenuated androgens (such as danazol)
are also prescribed for C1-INH-HAE attack prophylaxis. While admin-
istration of androgens is convenient, unacceptable adverse effects
(such as androgenic hormonal effects, intracranial hypertension, and
hepatocellular adenoma and carcinoma) and contraindications (includ-
ing pregnancy and pediatrics) limit their clinical use.10,11
Avoralstat (formerly BCX4161) is a potent, small molecule inhibitor
of kallikrein that was discovered at BioCryst Pharmaceuticals, Inc.12
Effective inhibition of kallikrein with an orally bioavailable small mole-
cule such as avoralstat may have significant benefits for patients with
C1-INH-HAE by reducing the frequency of angioedema attacks. In a
prior Phase 2 study, the safety and efficacy of avoralstat 400 mg taken
3 times per day were evaluated as a prophylactic treatment to reduce
the frequency of angioedema attacks in subjects with C1-INH-HAE.13
Treatment with avoralstat resulted in significantly fewer angioedema
attacks per week, demonstrating proof of concept for avoralstat in the
prevention of angioedema attacks in subjects with C1-INH-HAE. In the
Phase 2 study, treatment with avoralstat also showed statistically sig-
nificant improvements in subject quality of life (QoL), severity of dis-
ease, and number of attack-free days. Avoralstat was generally well
tolerated with no discontinuations due to drug-related adverse events
(AEs), no Grade 4 AEs or treatment-related serious adverse events
(SAEs), and few Grade 3 AEs or laboratory abnormalities.
This OPuS-2 Phase 3 study evaluated the efficacy and safety of
prophylactic avoralstat 300 and 500 mg administered 3 times per day
for 12 weeks compared with placebo, assessed the effects of avoral-
stat on C1-INH-HAE disease activity and angioedema attack charac-
teristics. This study also evaluated the effects of avoralstat on patients’
QoL and described the population pharmacokinetics (PK) of avoralstat.
2 | METHODS
2.1 | Study design
OPuS-2 was a Phase 3, multicenter, randomized, double-blind, pla-
cebo-controlled, parallel-group study performed at 46 centers in North
America and Europe. Eligible subjects, stratified by screening angioe-
dema attack rates (≥1 attack per week vs <1 attack per week), were
randomized in a 1:1:1 ratio to receive avoralstat 500 mg, avoralstat
300 mg, or placebo administered orally 3 times per day for 12 weeks.
Details of HAE attacks were recorded in an electronic diary. Attacks
were treated in accordance with the subject’s normal standard of care.
The OPuS-2 trial (www.clinicaltrials.gov ID# NCT02303626 and
EudraCT # 2014-002655-26) was approved by independent ethics
committees or institutional review boards. All patients provided writ-
ten informed consent.
2.2 | Subjects
Subjects aged ≥18 years of age with a clinical diagnosis of type 1 or
2 C1-INH-HAE as documented by either a low C1 INH antigenic
level (Type I HAE) or a normal C1-INH antigenic level and a low C1
INH functional level (Type II HAE) were eligible. Documentation of
minimum angioedema attack rate of 2 per month was required,
either by audit of medical record (at least 2 angioedema attacks per
month for 3 consecutive months within the 6 months prior to
screening) or a subject diary record of at least 4 unique angioedema
attacks collected in a run-in period of a maximum of 2 months, with
at least 1 attack occurring each month. Use of C1INH or tranexamic
acid within 7 days prior to the screening visit or expected use at any
time during the study was exclusionary. The use of androgens within
30 days was also an exclusion criterion unless the subject was
receiving a stable dose of androgens at least 90 days prior to the
screening visit, met the required angioedema attack frequency while
on the stable dose, and planned to remain on the current dose of
androgens during the study.
2.3 | Study treatment
Subjects received avoralstat 500 mg, avoralstat 300 mg, or placebo
administered orally 3 times per day for 12 weeks, and were asked to
avoid taking study drug with food. Study drug assignment was
blinded to the investigator and clinical site personnel, study subjects,
and study staff.
2.4 | Study measures
The primary efficacy outcome was weekly angioedema attack rate
based on the number of confirmed episodes. Secondary efficacy
endpoints included the weekly subject-reported attack rate, number
of attack-free days, the AE-QoL score, and the average attack sever-
ity score. Efficacy data collected included the number of angioedema
attacks and related details (timing, severity, duration of symptoms,
anatomical location, treatment used [if any]), number of attack-free
days, Angioedema Quality of Life (AE-QoL) Questionnaire,14,15 and
angioedema activity score (AAS,16). An angioedema attack was
defined as subject-reported indication of swelling at any location fol-
lowing a report of no swelling on the previous day. Abdominal
attacks were defined by abdominal pain with or without nausea or
vomiting; laryngeal attacks were defined by difficulty swallowing or
breathing, voice change, or lump or tightness in the throat. Periph-
eral attacks were defined by cutaneous swelling. Prior to inclusion in
efficacy analyses, each subject-reported angioedema attack was
reviewed by the investigator, and all attacks were reviewed and con-
firmed or rejected by an expert adjudication panel blinded to treat-
ment arm.
Plasma samples for determination of avoralstat concentrations
were collected at baseline (Day 1) and predose (trough) at the Week
4, 8, and 12 visits for all subjects. Subjects who consented to partici-
pate in a PK substudy had additional plasma samples drawn through
6 hours following the first dose on Day 1 and for one morning dose
at or between the Week 4 and Week 8 visits.
Safety was assessed by monitoring of adverse events (AEs) and
through clinical laboratory assessments, vital signs, electrocardiograms
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(ECGs), abdominal ultrasonography, and physical examinations. An
independent data monitoring committee periodically reviewed safety
data.
2.5 | Populations for analysis
The intent-to-treat (ITT) and safety populations included all subjects
who were randomized and received at least 1 dose of study drug.
2.6 | Statistical analysis
The primary efficacy endpoint was the angioedema attack rate based
on confirmed attacks. The study was designed to investigate the
superiority of avoralstat over placebo. Assuming a normalized placebo
attack rate of 1 unit and standard deviations of 0.45 and 0.40 units
for avoralstat and placebo attack rates, respectively, a sample size of
32 subjects was anticipated to have 90% power to detect a treat-
ment difference of 0.35 units per time period between avoralstat and
placebo, based on a 2-sided test at a significance level of 0.05.
An analysis of covariance (ANCOVA) model, including treatment
group as a fixed term and angioedema attack stratum (≥1 or <1 at-
tack per week) as a covariate, was used for the primary analysis,
which reported the estimated treatment difference in attack rate (for
each avoralstat dose minus placebo) with its associated 95% CI and
P-value.
Secondary efficacy endpoints included the number of attack-free
days, the AE-QoL score, the number of subject-reported attacks, and
the average attack severity score. Attack-free days were analyzed in
a similar manner as the primary efficacy endpoint. Changes from
baseline in AE-QoL data were summarized by the four AE-QoL
domain scores and a total score using the appropriate scoring algo-
rithm. Average attack severity score was summarized.
Avoralstat plasma PK parameters were estimated using noncom-
partmental analysis (Phoenix WinNonlin, version 6.4 or later).
Safety data were summarized descriptively.
3 | RESULTS
3.1 | Baseline characteristics
The study was conducted from December 2014 to January 2016.
Of the 137 subjects screened, 110 subjects were randomized and
dosed (Figure 1). Of the 110 subjects randomized, 103 subjects
(93.6%) completed study drug and 7 subjects (6.4%) discontinued
study drug prior to Week 12. Reasons for study drug discontinuation
included AEs (1 subject due to rash and 1 subject due to angioe-
dema attack in the avoralstat 500 mg group), lack of efficacy (1 sub-
ject each in the avoralstat 300 mg group and the placebo group), a
positive pregnancy test (1 subject in the placebo group), protocol
violation (1 subject in the avoralstat 500 mg group), and study non-
compliance (1 subject in the placebo group).
The majority of subjects were female (77.3%) and Caucasian
(92.7%), the mean age was 41.2 years, and the mean BMI was
26.8 kg/m2 (Table 1). A small number of subjects (9.1%) continued
with concurrent androgen prophylaxis on study. The mean (SD)
weekly qualifying attack rate was 0.93 (0.37). Baseline demographics





n = 137 Excluded n = 27Failed inclusion/exclusion n = 20
Consent withdrawn n = 4
Lost to follow-up n = 2
Investigator discretion n = 1
BCX4161 500 mg TID n = 38
Dosed n = 38
ITT n = 38
Safety n = 38
BCX4161 300 mg TID n = 36
Dosed n = 36
ITT n = 36
Safety n = 36
Placebo                      n = 36
Dosed n = 36
ITT n = 36
Safety n = 36
Discontinued drug     n = 3
AE                         n = 2
Protocol violation   n = 1
Discontinued drug     n = 1
Lack of efficacy  n = 1
Discontinued drug      n = 3
Lack of efficacy     n = 1
Non-compliance    n = 1
Withdrew consent n = 1 
Discontinued study n = 3
Protocol violation n = 1
Withdrew consent n = 2
Discontinued study n = 1
Withdrew consent n = 2
Discontinued study    n = 3
Non-compliance    n = 1
Withdrew consent n = 2
F IGURE 1 Consort diagram. AE, adverse event; ITT, intent to treat; TID, 3 times per day
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3.2 | Primary efficacy measure
The least squares (LS) mean attack rates per week of confirmed
attacks were 0.59, 0.68, and 0.59 for subjects during treatment with
avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respec-
tively (P ≥ .5, Table 2).
3.3 | Secondary efficacy measures
The LS mean attack rates per week of all subject-reported attacks
were 0.62, 0.73, and 0.65 for subjects in the avoralstat 500 mg, avo-
ralstat 300 mg, and placebo groups, respectively (P ≥ .5, Table 2).
The LS mean attack rates per week of confirmed attacks requiring
treatment were 0.49, 0.58, and 0.50 for subjects in the avoralstat
500 mg, avoralstat 300 mg, and placebo groups, respectively
(Table 2). The most commonly used medications to treat attacks
were icatibant and plasma-derived C1-INH concentrate.
Both the number and percent of attack-free days were similar
between active and placebo treatment groups, with approximately
80% of the total days on study treatment attack-free. Overall, 1 sub-
ject in each of the avoralstat groups and no subjects in the placebo
group were attack-free during the 84-day treatment period. The LS
mean duration of all confirmed attacks was 25.4, 29.4, and
31.4 hours for subjects in the avoralstat 500 mg (P = .01), avoralstat
300 mg (P = .40), and placebo groups, respectively.
The LS mean reduction from baseline (improvement) in total
AE-QoL scores in the avoralstat 500 mg group was significantly
greater than in the placebo group at Week 4 (7.23 points,
P = .03) and Week 8 (8.83 points, P = .01), but not at Week 12
(5.31 points, P = .16) (Table 3). Greater reductions were observed
for the avoralstat 500 mg group compared with placebo for each of
the individual domain scores with significant differences observed
at specific time points: Weeks 4 and 8 for functioning, Week 8 for
fear/shame, and Week 12 for fatigue/mood. No significant differ-
ences were observed between the avoralstat 300 mg group and
placebo at any time point.
Angioedema activity score scores were not significantly different
comparing either 500 mg or 300 avoralstat groups with placebo.
3.4 | Pharmacokinetics
Following multiple oral dose administration, maximal avoralstat con-
centrations were achieved approximately 1 hour postdose. Plasma
concentrations are shown in Figure 2. A large variability in plasma
concentrations was observed at both doses, with many time points
below the target therapeutic concentration of 4-8 times the EC50 of
avoralstat for plasma kallikrein.
3.5 | Safety
Avoralstat was generally safe and well tolerated, with only 2 dis-
continuations due to unrelated AEs (an angioedema attack, consid-
ered serious, and a mild rash; both in the avoralstat 500 mg group),
and no life-threatening AEs or treatment-related SAEs were
TABLE 1 Demographics and select baseline disease characteristics (ITT population)
Avoralstat 500 mg
TID (N = 38)
Avoralstat 300 mg





Age (years), mean (SD) 41.1 (15.1) 40.4 (12.4) 42.1 (12.5) 41.2 (13.3)
Sex (female), n (%) 30 (78.9) 29 (80.6) 26 (72.2) 85 (77.3)
Baseline BMI (kg/m2), mean (SD) 26.7 (4.5) 28.1 (5.4) 25.6 (3.9) 26.8 (4.7)
Race, n (%)
American Indian or Alaska Native 0 1 (2.8) 0 1 (0.9)
Asian 1 (2.6) 1 (2.8) 0 2 (1.8)
Native Hawaiian or Other Pacific Islander 0 1 (2.8) 1 (2.8) 2 (1.8)
White 36 (94.7) 32 (88.9) 34 (94.4) 102 (92.7)
Other 1 (2.6) 1 (2.8) 1 (2.8) 3 (2.7)
Hereditary angioedema type, n (%)
Type I 34 (89.5) 32 (88.9) 35 (97.2) 101 (91.8)
Type II 4 (10.5) 4 (11.1) 1 (2.8) 9 (8.2)
Age at diagnosis of C1-INH-HAE (years), mean (SD) 17.8 (10.6) 19.4 (12.1) 22.8 (12.1) 20.0 (11.7)
Qualifying attack rate (attack/week)a, mean (SD) 0.95 (0.39) 0.93 (0.39) 0.92 (0.34) 0.93 (0.37)
<1 attack per week, n (%) 26 (68.4) 26 (72.2) 22 (61.1) 74 (67.3)
≥1 attack per week, n (%) 12 (31.6) 10 (27.8) 14 (38.9) 36 (32.7)
Concurrent androgen use, n (%) 2 (5.3) 4 (11.1) 4 (11.1) 10 (9.1)
BMI, body mass index; C1-INH-HAE, hereditary angioedema due to C1 inhibitor deficiency; ITT, intent to treat; SD, standard deviation; TID, 3 times
per day.
aQualifying HAE attack rate was derived based on subject-reported historical attacks or attacks during the run-in period when historical attack data
were not available.
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reported. No deaths were reported. Most AEs were mild or moder-
ate in severity. Grade 3 AEs considered related to study drug were
flatulence, diarrhea, and abdominal distension in the avoralstat
300 mg group and flatulence and headache in the placebo group.
No Grade 3 AEs considered related to study drug were reported in
the 500 mg group. No treatment-emergent Grade 4 AEs were
reported.
The most commonly reported AEs (Table 4) in the combined
avoralstat groups and placebo, respectively, were diarrhea (32.4%,
33.3%), flatulence (20.3%, 25.0%), and nasopharyngitis (17.6%,
19.4%). The nature and frequency of the AEs were generally simi-
lar between the avoralstat treatment groups and the placebo
group.
Grade 3 or 4 chemistry abnormalities generally occurred in a
similar proportion of subjects in the avoralstat and placebo groups.
No subject experienced a Grade 3 or 4 hematology or coagulation
laboratory abnormality. No notable changes in vital signs (systolic
and diastolic blood pressure and pulse) were reported during the
study.
4 | DISCUSSION
This study failed to confirm the benefit of avoralstat in reducing
angioedema attack rates seen in the OPuS-1 Phase 2 study. With
the exception of quality of life, no differences were observed in the
prespecified secondary endpoints of the study, although the LS
mean attack duration for the avoralstat 500 mg group was signifi-
cantly less than placebo.
The failure of this Phase 3 study was surprising, given the clear
treatment effect demonstrated in the earlier Phase 2 study, OPuS-1.
A number of factors associated with the PK of avoralstat may
explain the poor outcome observed in this study.
Overall, reported study drug compliance was high with a
median compliance rate of approximately 99% across all treat-
ment groups. However, trough PK data indicate a wide spread
in the time since last recorded dose of study drug, indicating
that adherence to an 8-hourly dosing regimen and taking study
drug on an empty stomach, which were required due to the
short plasma half-life of the drug and known food effect on
TABLE 2 Summary of primary and secondary efficacy endpoints (ITT population)
Avoralstat 500 mg
TID (N = 38)
Avoralstat 300 mg
TID (N = 36)
Placebo
(N = 36)
Weekly rate of confirmed attacks
LS mean 0.59 0.68 0.59
Differencea (95% CI) 0.00 (0.25, 0.24) 0.08 (0.17, 0.33)
Treatment effect P-value .98 .51
Weekly rate of subject-reported attacks
LS mean 0.62 0.73 0.65
Differencea (95% CI) 0.03 (0.29,0.23) 0.08 (0.18, 0.35)
Treatment effect P-value .80 .53
Weekly rate of confirmed attacks requiring treatment
LS mean 0.49 0.58 0.50
Differencea (95% CI) 0.02 (0.27, 0.23) 0.07 (0.18, 0.32)
Attack duration hours
LS mean 25.4 29.4 31.4
Differencea (95% CI) 6.0 2.0
Treatment effect P-value .01 .40
Number of attack-free days
LS mean 67.2 64.1 64.2
Differencea (95% CI) 3.0 (4.5, 10.4) 0.1 (7.7, 7.5)
Treatment effect P-value .43 .98
Attack-free subjects
n (%) 1 (2.6) 1 (2.8) 0
AAS84
LS mean 83.94 109.08 94.84
Differencea (95% CI) 10.90 14.24
Treatment effect P-value .59 .49
AAS, angioedema activity score; AE-QoL, angioedema quality of life; CI, confidence interval; ITT, intent to treat; LS, least squares; TID, 3 times per day.
aAvoralstat – placebo.
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exposure, respectively, was a challenge for study subjects.
Intervals between the 3 daily doses were not evenly spaced,
with the largest mean interval of approximately 11 hours.
Thus, while reported dosing compliance was 99%, dosing
frequency (three times daily) and food effect likely impacted
efficacy outcomes by contributing to variability in drug
exposure.
Plasma concentrations of avoralstat were widely distributed,
with many time points showing drug levels below the target ther-
apeutic range of 4-8 times the EC50 of avoralstat for plasma kal-
likrein. This variability in exposure was likely due to a combination
of the low oral bioavailability of the drug and its relatively rapid
clearance,17 coupled with variation in dosing interval and food
effects.
Although there were no significant reductions in angioedema
attack rate with avoralstat compared with placebo, there was some
evidence suggesting that treatment with avoralstat 500 mg improved
quality of life. The AE-QoL scores in the avoralstat 500-mg group
showed a significant reduction (improvement) compared to placebo
at Weeks 4 and 8; however, the difference was not significant at
Week 12. QoL measures are increasingly being incorporated into
HAE treatment trials as clinically meaningful endpoints. While clearly
insufficient to prove efficacy in this study, the difference in QoL
scores between the avoralstat 500 mg group and placebo treatment
groups is intriguing as a potential indirect marker of pharmacody-
namic effect.
Overall, treatment with avoralstat 500 or 300 mg 3 times daily
for 12 weeks was generally safe and well tolerated with no treat-
ment-related SAEs. Gastrointestinal side effects were most common,
but did not lead to treatment discontinuation. Gastrointestinal
events common to all groups were most likely due to excipients as
the rates of these events were similar in drug-treated and placebo
groups.
In summary, this rigorous randomized controlled trial of avoral-
stat did not demonstrate efficacy in preventing angioedema
attacks in C1-INH-HAE patients. However, the study provided evi-
dence of shortened angioedema episodes and improved QoL mea-
sures in the avoralstat 500 mg treatment group compared to
placebo, and established safety of oral kallikrein inhibition in this
study cohort.
In the future, additional compounds of this drug class with
improved pharmacokinetic and pharmacodynamic profiles may be
of substantial therapeutic benefit in C1-INH-HAE. Ongoing
TABLE 3 Summary of the LS mean change from baseline in the total AE-QoL score (ITT population)










Avoralstat 500 mg 38 16.63 2.37 7.23 13.6, 0.8 .03
Avoralstat 300 mg 35 5.06 2.47 4.34 2.2, 10.9 .19
Placebo 33 9.41 2.14 — — —
Week 8
Avoralstat 500 mg 37 18.55 2.66 8.83 15.6, 2.1 .01
Avoralstat 300 mg 34 10.96 3.02 1.23 8.6, 6.1 .74
Placebo 33 9.72 2.08 — — —
Week 12
Avoralstat 500 mg 36 17.45 2.66 5.31 12.8, 2.2 .16
Avoralstat 300 mg 33 9.89 3.11 2.25 5.9, 10.4 .59
Placebo 33 12.14 2.64 — — —
AE-QoL, angioedema quality of life; CI, confidence interval; ITT, intent to treat; LS, least squares.
aA reduction in total score represents an improvement in QoL.























300 mg TID, n = 53
500 mg TID, n = 57
F IGURE 2 Avoralstat plasma concentrations. The blue bar
represents a target therapeutic concentration in the range of 4-
8 times the EC50 of avoralstat for plasma kallikrein in a plasma-
based assay17
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studies are investigating an oral once-daily kallikrein inhibitor with
improved bioavailability and a longer half-life.
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